Drug Prices
Drug Prices
Sally Pipes Discusses Prescription Drugs and Inflation Reduction Act on Eric Bolling: The Balance
Watch PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy discuss prescription drug costs and the so-called Inflation Reduction Act on “Eric Bolling: The Balance” on Newsmax TV.
Commentary
Drug price controls would limit new medicines
The Democrats’ budget reconciliation bill is winding its way through the Senate. Last week, Republican and Democratic senators met with the chamber’s parliamentarian to discuss whether the bill’s proposal for Medicare to negotiate the price of prescription drugs with manufacturers has a direct impact on government spending or tax revenue, as reconciliation ...
Drug Prices
NEW STUDY: Creating Two-Part Drug Pricing System Would Ensure Prices More Accurately Reflect How Patients
Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics ...
Sally Pipes Discusses Prescription Drugs and Inflation Reduction Act on Eric Bolling: The Balance
Watch PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy discuss prescription drug costs and the so-called Inflation Reduction Act on “Eric Bolling: The Balance” on Newsmax TV.
Drug price controls would limit new medicines
The Democrats’ budget reconciliation bill is winding its way through the Senate. Last week, Republican and Democratic senators met with the chamber’s parliamentarian to discuss whether the bill’s proposal for Medicare to negotiate the price of prescription drugs with manufacturers has a direct impact on government spending or tax revenue, as reconciliation ...
NEW STUDY: Creating Two-Part Drug Pricing System Would Ensure Prices More Accurately Reflect How Patients
Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics ...
